# VENTANA PD-L1 (SP142), a complimentary diagnostic immunohistochemistry (IHC) assay to ascertain tumor PD-L1 status for patients with metastatic urothelial cancer considering treatment with atezolizuma

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2020 · $200,000

## Abstract

"NCI Protocol: NRG-GY017 “Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer.”
Briefly, PD-L1 expression will be assessed using the rabbit anti-human PD-L1 antibody (clone SP142). Using IHC, PD-L1 expression will be scored in tumor cells (as percentage of PD-L1-expressing tumor cells: TC3≥50%, TC2≥5% and <50%, TC1≥1% and <5%, and TC0<1%) and tumor infiltrating immune cells (as percentage of tumor area: IC3≥10%, IC2≥5% and <10%, IC1≥1% and <5%, and IC0<1%).
To satisfy the primary objective of the study, the following will be assessed in response to sequential versus concurrent atezolizumab and radiation: (1) peripheral blood T Cell Receptor (TCR) clonality, and (2) peripheral blood expansion of TCR clones, including TCR clones identified in tumor samples. 
For assessment of the primary endpoint, pre-treatment FFPE tumor biopsies (to determine which TCR clones are present within the tumor), as well as pre-treatment and on-treatment bloods will be required."

## Key facts

- **NIH application ID:** 10273221
- **Project number:** 75N91019D00024-0-759102000003-8
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LEONARD FREEDMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $200,000
- **Award type:** —
- **Project period:** 2020-08-31 → 2021-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10273221

## Citation

> US National Institutes of Health, RePORTER application 10273221, VENTANA PD-L1 (SP142), a complimentary diagnostic immunohistochemistry (IHC) assay to ascertain tumor PD-L1 status for patients with metastatic urothelial cancer considering treatment with atezolizuma (75N91019D00024-0-759102000003-8). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10273221. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*